A signature of plasma exosomal miRNAs predict therapeutic efficacy to neoadjuvant immunotherapy in patients with non-small cell lung cancer.

Zhai W; Lin Y; Zhou Y; Wang Q; Zhao Z; Feng S; Rao B; Sun W; Wang Y; Zhou Z; Qin J; Long H

doi:10.1515/jtim-2025-0052

← 뒤로

A signature of plasma exosomal miRNAs predict therapeutic efficacy to neoadjuvant immunotherapy in patients with non-small cell lung cancer.

0/5 보강

Journal of translational internal medicine 2025 Vol.13(6) p. 614-617

Zhai W, Lin Y, Zhou Y, Wang Q, Zhao Z, Feng S, Rao B, Sun W, Wang Y, Zhou Z, Qin J, Long H

📖 무료 전문 🟢 PMC 전문 PMC12721357

PubMed ↗ DOI ↗ BibTeX ↓ RIS ↓

이 논문을 인용하기

↓ .bib ↓ .ris

APA Zhai W, Lin Y, et al. (2025). A signature of plasma exosomal miRNAs predict therapeutic efficacy to neoadjuvant immunotherapy in patients with non-small cell lung cancer.. Journal of translational internal medicine, 13(6), 614-617. https://doi.org/10.1515/jtim-2025-0052

MLA Zhai W, et al.. "A signature of plasma exosomal miRNAs predict therapeutic efficacy to neoadjuvant immunotherapy in patients with non-small cell lung cancer.." Journal of translational internal medicine, vol. 13, no. 6, 2025, pp. 614-617.

PMID 41438471 ↗

DOI 10.1515/jtim-2025-0052

같은 제1저자의 인용 많은 논문 (1)

Surgery after neoadjuvant immunochemotherapy versus immuno-chemoradiotherapy in patients with cN3 non-small cell lung cancer: A cohort study in two academic centers.
Lung cancer (Amsterdam, Netherlands) 2026